Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

Original Article

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study

Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae

Clin Mol Hepatol. 2022;28(2):196-206. Published online January 13, 2022

DOI: https://doi.org/10.3350/cmh.2021.0371

Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients

Wen-Yue Liu, Xiaofang Zhang, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Rafael S. Rios, Kenneth I. Zheng, Hong-Lei Ma, Xiao-Dong Wang, Qiuwei Pan, Robert J. de Knegt, Luca Valenti, Mohsen Ghanbari, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(2):183-195. Published online November 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0301

U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases

Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2022;28(1):77-90. Published online November 5, 2021

Cited By 3

DOI: https://doi.org/10.3350/cmh.2021.0188

Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes

Hydar El Jamaly, Guy D Eslick, Martin Weltman

Clin Mol Hepatol. 2022;28(1):52-66. Published online September 17, 2021

Cited By 2

DOI: https://doi.org/10.3350/cmh.2021.0205

Editorial

Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment

Ja-Young Kwon

Clin Mol Hepatol. 2022;28(1):50-51. Published online November 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0359

An analysis of polygenic risk scores for non-alcoholic fatty liver disease

Dae Won Jun

Clin Mol Hepatol. 2021;27(3):446-447. Published online May 21, 2021

DOI: https://doi.org/10.3350/cmh.2021.0133

Guideline

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho

Clin Mol Hepatol. 2021;27(3):363-401. Published online June 22, 2021

Cited By 27

DOI: https://doi.org/10.3350/cmh.2021.0178

Review

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee

Clin Mol Hepatol. 2021;27(2):257-269. Published online March 22, 2021

Cited By 19

DOI: https://doi.org/10.3350/cmh.2021.0067

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2021;27(2):221-235. Published online December 3, 2020

Cited By 11

DOI: https://doi.org/10.3350/cmh.2020.0239

The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

Erica Jennison, Christopher D. Byrne

Clin Mol Hepatol. 2021;27(1):22-43. Published online December 10, 2020

Cited By 18

DOI: https://doi.org/10.3350/cmh.2020.0129

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights

Kenichi Ikejima, Kazuyoshi Kon, Shunhei Yamashina

Clin Mol Hepatol. 2020;26(4):728-735. Published online October 1, 2020

Cited By 11

DOI: https://doi.org/10.3350/cmh.2020.0202

Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases

Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2020;26(4):715-727. Published online September 22, 2020

Cited By 9

DOI: https://doi.org/10.3350/cmh.2020.0173

The effect of moderate alcohol drinking in nonalcoholic fatty liver disease

Jong Hwa Choi, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2020;26(4):662-669. Published online September 25, 2020

Cited By 10

DOI: https://doi.org/10.3350/cmh.2020.0163

Letter to the Editor

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Dimitrios Patoulias, Michael Doumas

Clin Mol Hepatol. 2020;26(4):582-583. Published online September 25, 2020

DOI: https://doi.org/10.3350/cmh.2020.0264

Review

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

Cited By 13

DOI: https://doi.org/10.3350/cmh.2020.0137

Original Article

Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease

Nadia Soledad Alegre, Cecilia Claudia Garcia, Luis Ariel Billordo, Beatriz Ameigeiras, Daniel Poncino, Javier Benavides, Luis Colombato, Alejandra Claudia Cherñavsky

Clin Mol Hepatol. 2020;26(2):216-226. Published online December 5, 2019

Cited By 7

DOI: https://doi.org/10.3350/cmh.2019.0074

Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017

Seung Ha Park, Lindsay D. Plank, Ki Tae Suk, Yong Eun Park, Jin Lee, Joon Hyuk Choi, Nae Yun Heo, Jongha Park, Tae Oh Kim, Young Soo Moon, Hyun Kuk Kim, Hang Jea Jang, Ha Young Park, Dong Joon Kim

Clin Mol Hepatol. 2020;26(2):209-215. Published online November 4, 2019

Cited By 44

DOI: https://doi.org/10.3350/cmh.2019.0065

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma

Rahul Kumar, Boon-Bee George Goh, Jia-Wen Kam, Pik-Eu Chang, Chee-Kiat Tan

Clin Mol Hepatol. 2020;26(2):196-208. Published online January 9, 2020

Cited By 6

DOI: https://doi.org/10.3350/cmh.2019.0012

Editorial

Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?

Soung Won Jeong

Clin Mol Hepatol. 2020;26(2):185-186. Published online March 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0046

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?

Ju Hyun Shim

Clin Mol Hepatol. 2020;26(2):183-184. Published online March 12, 2020

Cited By 3

DOI: https://doi.org/10.3350/cmh.2020.0042

Original Article

Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes

Ebrahim Banitalebi, Mohammad Faramarzi, Samira Nasiri, Majid Mardaniyan, Vahid Rabiee

Clin Mol Hepatol. 2019;25(3):294-304. Published online May 30, 2019

Cited By 8

DOI: https://doi.org/10.3350/cmh.2018.0086

The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study

Laura Rotundo, Alana Persaud, Mirela Feurdean, Sushil Ahlawat, Hyun-seok Kim

Clin Mol Hepatol. 2018;24(4):392-401. Published online August 2, 2018

Cited By 22

DOI: https://doi.org/10.3350/cmh.2018.0011

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease

Saba Sayari, Hassan Neishaboori, Maryam Jameshorani

Clin Mol Hepatol. 2018;24(3):331-338. Published online June 12, 2018

Cited By 16

DOI: https://doi.org/10.3350/cmh.2018.0006

Editorial

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?

Yong Kyun Cho

Clin Mol Hepatol. 2018;24(3):299-301. Published online September 7, 2018

DOI: https://doi.org/10.3350/cmh.2018.1006

Review

Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification

Dong Ho Lee

Clin Mol Hepatol. 2017;23(4):290-301. Published online October 10, 2017

Cited By 57

DOI: https://doi.org/10.3350/cmh.2017.0042

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs

Stephen Caldwell

Clin Mol Hepatol. 2017;23(2):103-108. Published online May 10, 2017

Cited By 26

DOI: https://doi.org/10.3350/cmh.2017.0103

Original Article

Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea

Eun Haeng Jeong, Dae Won Jun, Yong Kyun Cho, Young Gil Choe, Seungho Ryu, Seung Min Lee, Eun Chul Jang

Clin Mol Hepatol. 2013;19(3):266-272. Published online September 30, 2013

Cited By 55

DOI: https://doi.org/10.3350/cmh.2013.19.3.266

Editorial

Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD

Wonseok Kang, Seung Up Kim

Clin Mol Hepatol. 2013;19(3):255-257. Published online September 30, 2013

Cited By 2

DOI: https://doi.org/10.3350/cmh.2013.19.3.255

Association of Nonalcoholic Fatty Liver Disease with Incident Dementia Later in Life Among Elder Adults

Byoung Seok Ye

Received April 9, 2022 Accepted May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0097 [Accepted]

1 | 2 |

Viewed By 7033	Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Viewed By 4142	Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
Viewed By 3638	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Viewed By 2826	KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications
Viewed By 2055	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Cited By 44	Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017
Cited By 33	Application of transient elastography in nonalcoholic fatty liver disease
Cited By 30	Novel biomarkers for the management of chronic hepatitis B
Cited By 30	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Cited By 29	Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Search